A 28-year-old woman with Guillain-Barré Syndrome is in the ICU on mechanical ventilation. She has severe dysautonomia with recurrent hypertensive episodes and bradycardia. She has contraindications to plasmapheresis (thrombocytopenia, sepsis). Which is the most appropriate immunomodulatory agent?

Explanation

## IVIG as First-Line in Severe GBS with Contraindications **Key Point:** IVIG remains the drug of choice even in severe GBS with contraindications to plasmapheresis, as it avoids the hemodynamic instability and vascular complications associated with plasma exchange. ### Why IVIG in This Clinical Scenario | Feature | IVIG | Plasmapheresis | Corticosteroids | |---------|------|-----------------|------------------| | **Efficacy in GBS** | Proven (Level 1) | Proven (Level 1) | Not effective | | **Hemodynamic effects** | Minimal | Significant (fluid shifts) | Variable | | **Vascular access needed** | No | Yes (critical) | No | | **Safe in thrombocytopenia** | Yes | No (bleeding risk) | Yes | | **Safe in sepsis** | Relative caution | Contraindicated | Relative caution | | **Dysautonomia management** | Supportive care | May worsen | Supportive care | ### Dysautonomia Management in GBS - **Monitoring:** Continuous cardiac and BP monitoring in ICU - **Hypertensive episodes:** Labetalol, esmolol, or nitroprusside as needed - **Bradycardia/asystole:** Atropine at bedside; temporary pacing capability - **Autonomic dysfunction:** NOT an indication to change immunotherapy **High-Yield:** The presence of dysautonomia does NOT change the choice of immunomodulatory agent — it only increases ICU monitoring requirements. ### Why Other Options Fail - **Methylprednisolone:** Corticosteroids are ineffective in acute GBS and may worsen outcomes - **Rituximab:** B-cell depletion has no proven role in acute GBS; reserved for CIDP and other chronic autoimmune neuropathies - **Interferon-beta:** No evidence in GBS; used in multiple sclerosis, not peripheral neuropathy **Clinical Pearl:** In severe GBS with respiratory failure and dysautonomia, the priority is ICU support (mechanical ventilation, vasopressor/inotropic support, careful fluid balance) PLUS IVIG — not a change in immunotherapy. [cite:Harrison 21e Ch 379]